Biotech Values

[vieuxblue]

There may be a better PFE buying opportunity after PFE withdraws Celebrex. No matter what the valuation issues, the public will sell down further.

So far as I understand the scientific issues, all Cox-2 inhibitors are implicated in the cardiac problems. I'm a bit surprised that Pfizer didn't withdraw the compound today and get it over with. As it now stands, if (and I think when) they later withdraw, they are more vulnerable to the type of lawsuits that now bedevil Merck.